Review: Thiazolidinediones increase risk of heart failure in type 2 diabetes: Commentary

Evidence-Based Medicine

Volumn 13, Issue 1, 2008, Pages 8-

  Singh, S O ^a   Byrne, Christopher D ^b   Wild, Sarah H ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; HEART FAILURE; HUMAN; LOW DRUG DOSE; LUNG EDEMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

EID: 39049137377     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.13.1.8     Document Type: Short Survey

References (2)

1. United States Food and Drug Administration. 29 August 2007. www.fda.gov/medwatch/safety/2007/safety07.htm#rosi_pio
2. European Medicines Agency. Questions and answers on the benefits and risks of rosiglitazone and pioglitazone. 18 October 2007. www.emea.europa.eu/pdfs/human/press/pr/48446407en.pdf